LMO2 Is a Novel Predictive Marker for a Better Prognosis in Pancreatic Cancer

Nakata, Kohei; Ohuchida, Kenoki; Nagai, Eishi; Hayashi, Akifumi; Miyasaka, Yoshihiro; Kayashima, Tadashi; Yu, Jun; Aishima, Shinichi; Oda, Yoshinao; Mizumoto, Kazuhiro; Tanaka, Masao; Tsuneyoshi, Masazumi

doi:10.1593/neo.09418

Cited by 40 publications

(31 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, molecular biomarkers such as RhoA expression, LMO2 expression, or Skp2 expression have also been suggested as novel predictive markers for pancreatic carcinoma [21,22,23]. We have reported that the KRAS mutation predicts poor survival in patients with pancreatic cancer [24].…”

Section: Discussionmentioning

confidence: 99%

A Prognostic Model to Predict Clinical Outcomes with First-Line Gemcitabine-Based Chemotherapy in Advanced Pancreatic Cancer

Lee

Park

et al. 2011

Oncology

View full text Add to dashboard Cite

Objective: Our aim was to devise a prognostic model for advanced pancreatic cancer based on clinical parameters. Methods: We retrospectively analyzed the medical records of 298 patients who received gemcitabine-based chemotherapy from January 1999 to November 2008. Results: The median survival of all patients was 7 months [95% confidence interval (CI) 6.2–7.8]. Multivariate analysis revealed poor prognostic factors for overall survival such as the presence of liver metastasis [p < 0.001, hazard ratio (HR) 2.628, 95% CI 1.620–4.264], the presence of ascites or peritoneal carcinomatosis (p = 0.005, HR 1.783, 95% CI 1.194–2.661), serum C-reactive protein levels >1.2 mg/dl (p = 0.021, HR 1.568, 95% CI 1.070–2.300), and serum albumin levels <3.5 g/dl (p = 0.021, HR 1.701, 95% CI 1.085–2.667). Of 298 patients, 168 patients (56.4%) were categorized as low-risk with 0 or 1 risk factor, 80 patients (26.8%) were categorized as intermediate-risk with 2 risk factors, and 50 patients (16.8%) were categorized as high-risk with 3 or 4 risk factors. The median survival duration for the low-, intermediate-, and high-risk groups was 10.0 months (95% CI 8.7–11.3), 6.7 months (95% CI 5.7–7.7), and 4.4 months (95% CI 3.2–5.6), respectively. Conclusions: This prognostic model could help to select treatment for patients in clinical practice, and these risk-adapted treatment strategies should be further investigated in prospective studies in such patient populations.

show abstract

Section: Discussionmentioning

confidence: 99%

A Prognostic Model to Predict Clinical Outcomes with First-Line Gemcitabine-Based Chemotherapy in Advanced Pancreatic Cancer

Lee

Park

et al. 2011

Oncology

View full text Add to dashboard Cite

show abstract

“…The role of LMO2 as oncogene in T-ALL 6 and, conversely, as favorable prognostic factor in DLBCL, 8 CML 9 and pancreatic cancer, 10 led us to evaluate the practically unexplored role of LMO2 in B-ALL. We found that LMO2 is expressed in this disease, as previously proposed.…”

Section: Discussionmentioning

confidence: 99%

“…12,13 Full clinical and laboratory data were available for 39 T-ALL and 145 B-ALL patients (one of them lacking survival data) with a median age of 11.5 years (range 0.5-87 years), including 100 children under 15 years of age (median 5.5 years, range 0. [5][6][7][8][9][10][11][12][13][14] and 84 patients over 15 years of age (mean age 34.5, range 15-87). Sample collection was approved by the individual institutional review boards of the participating institutions and informed consent was obtained from all adult patients and children's parents or legal guardians.…”

Section: Patients' Samples and Cell Linesmentioning

confidence: 99%

“…2 Remarkably, LMO2 expression is an independent prognostic factor of survival in patients with DLBCL treated with anthracyclinebased chemotherapy with and without rituximab, 8 as well as in chronic myeloid leukemia 9 and pancreatic cancer. 10 While marked advances have been made in establishing the significance and function of LMO2 in T-ALL and B-cell lymphomas, its role in B-cell acute lymphoblastic leukemia (B-ALL) has not been investigated.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome

Malumbres¹,

Fresquet²,

Román‐Gómez³

et al. 2011

Haematologica

View full text Add to dashboard Cite

We measured LMO2 expression by real time RT-PCR in 247 acute lymphoblastic leukemia patient samples with cytogenetic data (144 of them also with survival and immunophenotypical data) and in normal hematopoietic and lymphoid cells. ResultsB-cell acute lymphoblastic leukemia cases expressed variable levels of LMO2 depending on immunophenotypical and cytogenetic features. Thus, the most immature subtype, pro-B cells, displayed three-fold higher LMO2 expression than pre-B cells, common-CD10+ or mature subtypes. Additionally, cases with TEL-AML1 or MLL rearrangements exhibited two-fold higher LMO2 expression compared to cases with BCR-ABL rearrangements or hyperdyploid karyotype. Clinically, high LMO2 expression correlated with better overall survival in adult patients (5-year survival rate 64.8% (42.5%-87.1%) vs. 25.8% (10.9%-40.7%), P= 0.001) and constituted a favorable independent prognostic factor in B-ALL with normal karyotype: 5-year survival rate 80.3% (66.4%-94.2%) vs. 63.0% (46.1%-79.9%) (P= 0.043). ConclusionsOur data indicate that LMO2 expression depends on the molecular features and the differentiation stage of B-cell acute lymphoblastic leukemia cells. Furthermore, assessment of LMO2 expression in adult patients with a normal karyotype, a group which lacks molecular prognostic factors, could be of clinical relevance.

show abstract

“…Total RNA was isolated from FFPE tissue samples using the RNeasy FFPE kit (Qiagen, Tokyo, Japan) with some modification to the manufacturer's instructions after macrodissection based on a review of representative hematoxylin and eosin-stained slides as described previously (19). Total RNA was extracted from cells isolated by microdissection according to the standard acid guanidinium thiocyanate-phenol-chloroform protocol (20), with or without glycogen (Funakoshi, Tokyo, Japan).…”

Section: Methodsmentioning

confidence: 99%

High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy

et al. 2011

View full text Add to dashboard Cite

Abstract. Pancreatic ductal adenocarcinoma (PDAC) still presents a major therapeutic challenge and a phase III clinical trial has revealed that the combination of gemcitabine and a human epidermal growth factor receptor type I (HER1/ EGFR) targeting agent presented a significant benefit compared to treatment with gemcitabine alone. The aim of this study was to investigate EGFR mRNA expression in resected PDAC tissues and its correlation with patient prognosis. We obtained formalin-fixed paraffin-embedded (FFPE) tissue samples from 88 patients with PDAC who underwent pancreatectomy, and measured EGFR mRNA levels by quantitative real-time reverse transcription-polymerase chain reaction. The highlevel EGFR group had significantly shorter disease-free-survival (p= 0.029) and overall-survival (p= 0.014) as shown by univariate analyses, although these did not reach statistical significance, as shown by multivariate analyses. However, we found that high EGFR expression was an independent prognostic factor in patients receiving gemcitabine-based adjuvant chemotherapy (p=0.023). Furthermore, we measured EGFR mRNA levels in 20 endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) cytological specimens. Altered EGFR levels were distinguishable in microdissected neoplastic cells from EUS-FNA cytological specimens compared to those in whole cell pellets. In conclusion, quantitative analysis of EGFR mRNA expression using FFPE tissue samples and microdissected neoplastic cells from EUS-FNA cytological specimens could be useful in predicting prognosis and sensitivity to gemcitabine in PDAC patients.

show abstract

LMO2 Is a Novel Predictive Marker for a Better Prognosis in Pancreatic Cancer

Abstract: LMO2 is a promising marker for predicting a better prognosis in pancreatic cancer.

Cited by 40 publications

References 21 publications

A Prognostic Model to Predict Clinical Outcomes with First-Line Gemcitabine-Based Chemotherapy in Advanced Pancreatic Cancer

A Prognostic Model to Predict Clinical Outcomes with First-Line Gemcitabine-Based Chemotherapy in Advanced Pancreatic Cancer

LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome

High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy

Contact Info

Product

Resources

About